Anil Koul

Prof. Anil Koul


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Nature
Verified
Journal Article
Open access
PDF file
EDEllen Van Damme
Ellen Van Damme
PAPravien Abeywickrema
Pravien Abeywickrema
YYYanting Yin
Yanting Yin
JXJiexiong Xie
Jiexiong Xie
SJSofie Jacobs
Sofie Jacobs
MLMarnix Van Loock
Marnix Van Loock
The membrane (M) protein of betacoronaviruses is well conserved and has a key role in viral assembly1,2. Here we describe the identification of JNJ-9676, a small-molecule inhibitor targeting the coronavirus M protein. JNJ-9676 demonstrates in vitro nanomolar antiviral activity against SARS-CoV-2, SARS-CoV and sarbecovirus strains from bat and pangolin zoonotic origin. Using cryogenic electron microscopy (cryo-EM), we determined a binding pocket of JNJ-9676 formed by the transmembrane domains of the M protein dimer. Compound binding stabilized the M protein dimer in an altered conformational state between its long and short forms, preventing the release of infectious virus. In a pre-exposure Syrian golden hamster model, JNJ-9676 (25 mg per kg twice per day) showed excellent efficacy, illustrated by a significant reduction in viral load and infectious virus in the lung by 3.5 and 4 log10-transformed RNA copies and 50% tissue culture infective dose (TCID50) per mg lung, respectively. Histopathology scores at this dose were reduced to the baseline. In a post-exposure hamster model, JNJ-9676 was efficacious at 75 mg per kg twice per day even when added at 48 h after infection, when peak viral loads were observed. The M protein is an attractive antiviral target to block coronavirus replication, and JNJ-9676 represents an interesting chemical series towards identifying clinical candidates addressing the current and future coronavirus pandemics.

18 June 2025 in Nature
Verified
Journal Article
Open access
PDF file
DLDirk A. Lamprecht
Dirk A. Lamprecht
RWRichard J. Wall
Richard J. Wall
ALAnnelies Leemans
Annelies Leemans
BTBarry Truebody
Barry Truebody
JSJoke Sprangers
Joke Sprangers
Anil KoulAnil Koul
Anil Koul
Tuberculosis remains the leading cause of death from an infectious disease1,2. Here we report the discovery of a first-in-class small-molecule inhibitor targeting PurF, the first enzyme in the mycobacterial de novo purine biosynthesis pathway. The lead candidate, JNJ-6640, exhibited nanomolar bactericidal activity in vitro. Comprehensive genetic and biochemical approaches confirmed that JNJ-6640 was highly selective for mycobacterial PurF. Single-cell-level microscopy demonstrated a downstream effect on DNA replication. We determined the physiologically relevant concentrations of nucleobases in human and mouse lung tissue, showing that these levels were insufficient to salvage PurF inhibition. Indeed, proof-of-concept studies using a long-acting injectable formulation demonstrated the in vivo efficacy of the compound. Finally, we show that inclusion of JNJ-6640 could have a crucial role in improving current treatment regimens for drug-resistant tuberculosis. Together, we demonstrate that JNJ-6640 is a promising chemical lead and that targeting de novo purine biosynthesis represents a novel strategy for tuberculosis drug development.

21 October 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JPJody Phelan
Jody Phelan
KHKlaas Van Den Heede
Klaas Van Den Heede
SMSerge Masyn
Serge Masyn
RVRudi Verbeeck
Rudi Verbeeck
TCTaane G. Clark
Taane G. Clark
RWRichard J. Wall
Richard J. Wall
Tuberculosis (TB) remains one of the leading infectious disease killers in the world. The ongoing development of novel anti-TB medications has yielded potent compounds that often target single sites with well-defined mechanisms of action. However, despite the identification of resistance-associated mutations through target deconvolution studies, comparing these findings with the diverse Mycobacterium tuberculosis populations observed in clinical settings is often challenging. To address this gap, we constructed an open-access database encompassing genetic variations from > 50,000 clinical isolates, spanning the entirety of the M. tuberculosis protein-encoding genome. This resource offers a valuable tool for investigating the prevalence of target-based resistance mutations in any drug target within clinical contexts. To demonstrate the practical application of this dataset in drug discovery, we focused on drug targets currently undergoing phase II clinical trials. By juxtaposing genetic variations of these targets with resistance mutations derived from laboratory-adapted strains, we identified multiple positions across three targets harbouring resistance-associated mutations already present in clinical isolates. Furthermore, our analysis revealed a discernible correlation between genetic diversity within each protein and their predicted essentiality. This meta-analysis, openly accessible via a dedicated dashboard, enables comprehensive exploration of genetic diversity pertaining to any drug target or resistance determinant in M. tuberculosis.

22 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CAClara Aguilar-Pérez
Clara Aguilar-Pérez
ALAnne J. Lenaerts
Anne J. Lenaerts
CVCristina Villellas
Cristina Villellas
JGJerome Guillemont
Jerome Guillemont
JDJohn Dallow
John Dallow
DLDirk A. Lamprecht
Dirk A. Lamprecht
Tuberculosis (TB) remains the foremost cause of death from infectious diseases globally, prompting ongoing efforts to improve treatment options. This includes developing compounds with novel modes of action and identifying optimal treatment regimens that allow for treatment shortening. One promising strategy involves targeting cytochrome bc 1 oxidase in Mycobacterium tuberculosis , a key enzyme in the respiratory chain. In this study, we evaluate the potential of cytochrome bc 1 inhibitors as partner drugs in TB combination regimens. Using a relapsing mouse model, we demonstrate that these inhibitors enhance regimen sterilisation and significantly reduce the time required for effective treatment. We also propose several novel combination strategies for both multidrug-resistant and drug-sensitive TB, where cytochrome bc 1 inhibitors contribute to sterilisation and improved treatment outcomes. Furthermore, M. tuberculosis clinical isolates exhibited heightened susceptibility to cytochrome bc 1 inhibitors compared to laboratory-adapted strains, highlighting the importance of using clinical isolates in TB drug discovery to better reflect the diversity of TB populations. These findings emphasise the potential of cytochrome bc 1 inhibition in the development of more effective and shorter treatment regimens for TB, supporting the need for further clinical investigation.

21 February 2025 in Research Square
Verified
Preprint
Open access
PDF file
OGOlivia Goethals
Olivia Goethals
DBDoortje Borrenberghs
Doortje Borrenberghs
KCKitti Chan
Kitti Chan
SBSven Van Brandt
Sven Van Brandt
SJSteffen Jaensch
Steffen Jaensch
Anil KoulAnil Koul
Anil Koul
Flaviviruses, such as dengue virus (DENV), Zika virus (ZIKV), West Nile virus (WNV), Japanese encephalitis virus (JEV), and yellow fever virus (YFV), constitute a significant public health concern with billions of people at risk of infection. Climate change and the expanding geographical distribution of mosquito vectors transmitting flaviviruses have increased their potential to cause large-scale disease outbreaks. The frequency and severity of disease outbreaks highlights the urgent need for a broad-spectrum antiviral agent targeting flaviviruses. In this work, we conducted a comprehensive morphological profiling of approximately 200,000 small molecules through a fluorescence-based high-content imaging platform, which led to the identification of a singular small molecule exhibiting broad-spectrum activity against flaviviruses. Subsequent hit deconvolution against DENV serotype 2 (DENV-2) revealed NS2A as a novel therapeutic target and suggested a mechanism whereby the identified small molecule inhibits the interaction between NS2A and the prM protein, revealing a previously uncharacterized antiviral mechanism of action.

4 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JPJody Phelan
Jody Phelan
KHKlaas Van Den Heede
Klaas Van Den Heede
SMSerge Masyn
Serge Masyn
RVRudi Verbeeck
Rudi Verbeeck
TCTaane G. Clark
Taane G. Clark
RWRichard J. Wall
Richard J. Wall